Harbin Medisan Pharmaceutical Co., Ltd.
Symbol: 002900.SZ
SHZ
10.31
CNYMarknadspris idag
62.4601
P/E-tal
1.8348
PEG-kvot
3.19B
MRK Aktiekapital
- 0.01%
DIV Avkastning
{{företagets_namn}} (002900-SZ) Finansiella rapporter
Balansräkning
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1048.9 | 1293.9 | 1111.5 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 57.8 | 91.3 | 581.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 150.6 | 164.1 | 149.6 | ||||||||||||
balance-sheet.row.inventory | 0 | 208.8 | 161.2 | 156.5 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 28.2 | 4.5 | 9.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1436.4 | 1623.7 | 1427.2 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1081.6 | 882.4 | 925.3 | ||||||||||||
balance-sheet.row.goodwill | 0 | 1.3 | 0.5 | 9.4 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 141.2 | 71.7 | 62.5 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 142.5 | 72.2 | 71.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 651.2 | 555.6 | 22.8 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 23.1 | 23.8 | 25.8 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 108.1 | 119.1 | 592.4 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 2006.5 | 1653.1 | 1638.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 182.1 | 120.8 | 105.2 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 480.2 | 233.8 | 274.8 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 3.1 | 12.2 | 11.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 238.2 | 422.9 | 212.9 | ||||||||||||
Deferred Revenue Non Current | 0 | 79 | 83.9 | 89 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 7.9 | 188.3 | 2.5 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 449.7 | 627.1 | 412.4 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 8.3 | 5.1 | 8 | ||||||||||||
balance-sheet.row.total-liab | 0 | 1294.8 | 1224.8 | 949 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 316.4 | 316.6 | 316.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 612.9 | 570.7 | 639.6 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 162.5 | 192.3 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1211.2 | 990.9 | 952.9 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2140.5 | 2040.7 | 2101.4 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 7.7 | 11.3 | 15 | ||||||||||||
balance-sheet.row.total-equity | 0 | 2148.2 | 2052 | 2116.5 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 709 | 646.9 | 604.5 | ||||||||||||
balance-sheet.row.total-debt | 0 | 718.4 | 656.7 | 487.7 | ||||||||||||
balance-sheet.row.net-debt | 0 | -272.8 | -545.9 | -42.2 |
Kassaflödesanalys
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 26.5 | 349.7 | 26.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 106.6 | 99.1 | 79.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | -11.7 | -95 | 1.4 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 49.5 | 107.4 | -160.1 | |||||||||||
cash-flows.row.account-receivables | 0 | -10 | 49.6 | 49.1 | |||||||||||
cash-flows.row.inventory | 0 | 0.6 | 26.5 | 31.9 | |||||||||||
cash-flows.row.account-payables | 0 | 47.2 | -63.7 | -239.6 | |||||||||||
cash-flows.row.other-working-capital | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | -37.9 | -568.8 | 49 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0.3 | 11.6 | 146.4 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -72 | -1113.7 | -1091 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 580.2 | 901.9 | 1437.6 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -4.1 | -145.9 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 419.3 | -278.2 | 201.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -270.2 | -269.5 | -230 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -109.3 | -34.3 | -95.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 272.4 | 260.1 | 323.2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -107.1 | -43.7 | -2.6 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 456.8 | -334.5 | 194.2 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 782.3 | 325.5 | 660 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 325.5 | 660 | 465.7 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 144.6 | -12.5 | -4.5 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 55.4 | -86.5 | -150.4 |
Resultaträkning rad
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1186.8 | 1028.4 | 945.8 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 476.4 | 365.6 | 309.4 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 710.4 | 662.8 | 636.4 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 693.4 | 679.6 | 765.2 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1169.7 | 1045.1 | 1074.6 | ||||||||||||
income-statement-row.row.interest-income | 0 | 27.9 | 28.3 | 11.8 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 108.7 | 106.6 | 122.9 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 79 | 57.6 | 454.8 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 81.4 | 40.1 | 452.9 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 11.3 | 13.6 | 103.2 | ||||||||||||
income-statement-row.row.net-income | 0 | 73.7 | 30.2 | 351 |
Ofta ställda frågor
Vad är Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) totala tillgångar?
Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) totala tillgångar är 3442984089.000.
Vad är företagets årliga omsättning?
Den årliga intäkten är N/A.
Vad är företagets vinstmarginal?
Företagets vinstmarginal är 0.582.
Vad är företagets fria kassaflöde?
Fritt kassaflöde är -1.022.
Vad är företagets nettovinstmarginal?
Nettovinstmarginalen är 0.049.
Vad är företagets totala intäkter?
Totala intäkter är 0.026.
Vad är Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) nettovinst (nettoinkomst)?
Nettovinst (nettoinkomst) är 73663110.000.
Vad är företagets totala skuldsättning?
Den totala skulden är 718376453.000.
Vad är rörelsens kostnader?
Rörelsens kostnader är 693357200.000.
Vad är företagets kassaflöde?
Företagets kassa är 0.000.